U.K. NRT Harm Reduction Indication Could Be Model For U.S.
This article was originally published in The Tan Sheet
Executive Summary
The U.K.'s harm reduction indication for a nonprescription nicotine replacement therapy inhaler could bode well for GlaxoSmithKline's request that FDA allow a similar change for NRT products in the U.S